Demo Patient View

What is the potential treatment?

Tulisokibart is a potential treatment developed to manage active, moderate to severe UC. Researchers aim to determine how well this treatment works and whether more people receiving the medication experience symptom relief compared to those receiving a placebo. A placebo contains no active substance. The use of a placebo helps researchers better understand the effectiveness of the new treatment.

Ulcerative Colitis (UC)

UC is an inflammatory bowel disease (IBD) that causes swelling and ulcers in the digestive tract. It affects the lining of the colon, including the rectum. People with ulcerative colitis often experience periods with few or no symptoms, followed by periods of symptom flare-ups. The disease is rarely life-threatening but can have a significant impact on quality of life. Therefore, finding effective treatment options is important.

What treatments are given in the study?

Participants will receive one or both of the following treatments:

• Placebo.
• Tulisokibart, the investigational drug, at different doses.

Both the active drug and placebo will be administered:

• Intravenously (infusion into a vein).
• As an injection under the skin at different times during the study.